XML 38 R26.htm IDEA: XBRL DOCUMENT
v3.21.2

Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual) |  |  |  | 3 Months Ended | 6 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 26, 2021 EUR (€) | Jun. 24, 2020 | Jun. 30, 2017 USD ($) | Jun. 30, 2017 EUR (€) | Jun. 30, 2021 USD ($) | Jun. 30, 2020 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2020 USD ($) | Jul. 08, 2021 shares | Dec. 31, 2020 USD ($) | Dec. 01, 2020 | Apr. 26, 2019 | Jun. 30, 2017 EUR (€)
Cost of Goods and Services Sold, Total |  |  |  |  | $ 829,504 | $ 624,240 | $ 1,220,266 | $ 902,422 |  |  |  |  |
Research and Development Expense, Total |  |  |  |  | 2,209,242 | $ 1,116,163 | 4,017,340 | $ 1,871,616 |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement |  |  | $ 1,100,000 |  |  |  |  |  |  |  |  |  |
Novovet [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  | 20.00% |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Sale of Stock, Percentage of Ownership after Transaction |  | 2.50% |  |  |  |  |  |  |  |  |  |  |
Equity Securities without Readily Determinable Fair Value, Amount |  |  |  |  |  |  |  |  |  | $ 284,709 |  |  |
BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of Goods and Services Sold, Total |  |  |  |  | 33,000 |  | 48,000 |  |  |  |  |  |
Research and Development Expense, Total |  |  |  |  | $ 33,000 |  | $ 33,000 |  |  |  |  |  |
Subsequent Event [Member] | BDI Holdings and VLPBio [Member] | Discontinued Operations, Disposed of by Sale [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from Divestiture of Businesses and Interests in Affiliates, Total | € | € 1,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Additional Development and Commercialization | € |  |  |  |  |  |  |  |  |  |  |  |  | € 1,500,000
Service Framework Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development |  |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Duration Of Agreement (Year) |  |  | 2 years | 2 years |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Outstanding Commitment |  |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |
BDI Holdings [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage | 16.10% |  |  |  |  |  |  |  |  |  |  |  |
VLPBio Member | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage | 3.30% |  |  |  |  |  |  |  |  |  |  |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  |  |  | 1.99% |  |
ID Biologics Inc [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Investment Owned, Balance, Shares (in shares) | shares |  |  |  |  |  |  |  |  | 129,661 |  |  |  |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |  |  |  |  |  |  |  |  | 0.37% |  |  |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement | € |  |  |  | € 1,000,000.0 |  |  |  |  |  |  |  |  |
Research Services Agreement [Member] | BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  |  | 16.10% | 16.10% |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  |  |  |  | 936,000
Collaborative Arrangement, Duration Of Agreement (Year) |  |  | 2 years | 2 years |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Maximum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  |  |  |  | 8,000,000.0
Research Services Agreement [Member] | BDI Holdings [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  |  |  |  | € 1,000,000
Collaborative Arrangement, Revenue Sharing, Percentage |  |  | 50.00% | 50.00% |  |  |  |  |  |  |  |  |
Research Services Agreement [Member] | BDI Holdings [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Revenue Sharing, Percentage |  |  | 75.00% | 75.00% |  |  |  |  |  |  |  |  |
Research Services Agreement [Member] | VLPBio Member |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  |  | 3.30% | 3.30% |  |  |  |  |  |  |  |  |

X
- Definition Represents duration of agreement for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementDurationOfAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents equity interest acquired for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents maximum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents minimum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents outstanding commitment for collaborative. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOutstandingCommitment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payments for additional development and commercialization for collaborative arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payment for research and development agreement for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents percentage of revenue sharing for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementRevenueSharingPercentage
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents ownership percentage by noncontrolling owners for noncontrolling interest. + References No definition available. + Details
Name: | dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of ownership. + References No definition available. + Details
Name: | dyai_OwnershipPercentage
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dyai_BDIHoldingsAndVLPBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=dyai_ServiceFrameworkAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_VLPBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_IDBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |